There are 2949 resources available
Invited Discussant 1020O and 1021O
Presenter: Maria Rescigno
Session: Proffered Paper - Investigational immunotherapy
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Silvia Formenti
Session: Proffered Paper - Investigational immunotherapy
Resources:
Webcast
Invited Discussant 1156O and 1160O
Presenter: Eva Segelov
Session: Proffered Paper - NETs
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Eva Segelov
Session: Proffered Paper - NETs
Resources:
Webcast
Invited Discussant 1157O and 1913O
Presenter: Nicola Fazio
Session: Proffered Paper - NETs
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Eva Segelov
Session: Proffered Paper - NETs
Resources:
Webcast
1021O - Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies
Presenter: Michael Millward
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1156O - Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)
Presenter: Jianming Xu
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1160O - An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis
Presenter: Guillaume Nicolas
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1157O - A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
Presenter: Jaume Capdevila
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast